Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

NRTIs

Phase 3Small molecule

NRTIs is one of 68 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

2

Indications

9

Total Trials

0

Active Trials

67

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

ImmunodeficiencyActive, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

ImmunodeficiencyPhase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Sovaldi

Virazole

CConrado Roberto Hoffmann Filho

NRTIs

Incivek

Vertex Pharmaceuticals

Roferon-a

Dasabuvir

SOF/VEL

Peg-IFN Alfa-2b

Debio 025

DDebiopharm International SA

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tenofovir2 trials

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Completed· Gilead logo

Gilead·Phase 3·NCT01252940·482 enrolled

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Completed· Gilead logo

Gilead·Phase 3·NCT03631732·496 enrolled

Interaction1 trial

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01903031·84 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Completed· Gilead logo

Gilead·Phase 3·NCT01440569·314 enrolled

Adult1 trial

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

Unknown status·KKirby Institute·Phase 4·NCT03017872·831 enrolled

Inflammation1 trial

Inflammation and Co-Infections in D²EFT

Withdrawn·KKirby Institute·Phase 4·NCT04183738

3 more indications

Chronic Hepatitis1 trial

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors

Completed·HHuahui Health·Phase 2·NCT05839639·73 enrolled

Treatment1 trial

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2/3·NCT00039741·266 enrolled

Immunodeficiency1 trial

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01516970·312 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for NRTIs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NRTIs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NRTIs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Gilead

Related News